Recently, the AURKA inhibitor MLN8237 (Alisertib) entered clinical trials, and experimental studies have demonstrated that MLN8237 exhibits a strong synergistic effect with Sorafenib in HCC models [41,42]. This evidence concerns the gene AURKA and hepatocellular carcinoma.